- Home
- / UCB
UCB
Patients Reached
3.5 M
FY, 2020
Revenue
€5.5 B
FY, 2021
Market Capitalization
€14.5 B
2023-01-23
UCB Summary
Company summary
- Overview
- UCB is a biopharma company, focusing on neurology and immunology. It develops products for the treatment of epilepsy, Parkinson's disease, restless legs syndrome, ankylosing spondylitis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis.
- Type
- Public
- Status
- Active
- Founded
- 1928
- HQ
- Anderlecht, BE | view all locations
- Website
- http://www.ucb.com/
- Cybersecurity rating
- ESG rating
Key people
Kirsten Lund-Jurgensen, Executive Vice President of Supply & Technology Solutions
Dhavalkumar Patel, Executive Vice President & Chief Scientific Officer
Emmanuel Caeymaex, Executive Vice President of Immunology Solutions & Head of US
Operating MetricsView all
Patients Reached
3.5M
FY, 2020
Projects in Pipeline
12
71.4%
FY, 2020
Locations (Research and Development)
12
FY, 2019
LocationsView all
40 locations detected
Anderlecht, Bruxelles HQ
Belgium
60 Allée de la Recherche
Raleigh, NC
United States
8010 Arco Corporate Dr
Smyrna, GA
United States
1950 Lake Park Dr SE
Malvern, VIC
Australia
Level 1/1155 Malvern Rd
Wien, Wien
Austria
Twin Tower Wienerbergstrasse 11/12a
Braine-l'Alleud, Wallonie
Belgium
Chemin du Foriest
UCB Financials
Summary financials
- Revenue (H1, 2022)
- €2.7B
- Gross profit (H1, 2022)
- €2.5B
- Net income (H1, 2022)
- €399.0M
- Cash (H1, 2022)
- €515.0M
- EBIT (H1, 2022)
- €490.0M
- Enterprise value
- $17.0B
